Authors
Latest:
Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual MeetingKey opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Latest:
Mount Sinai Achieves Highest Rating From Society of Thoracic Surgeons for Ground-Breaking Esophagectomy ProgramThe Mount Sinai Health System's esophagectomy program has received a three-star overall composite score from the Society of Thoracic Surgeons.
Latest:
Final Thoughts on Recent Data Updates in MDSClosing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.
Latest:
Recent Updates in Early Onset Colorectal Cancer: What We Know and Where to GoOncologists globally explore trends, challenges in diagnosis, and future directions in patients with colorectal cancer.
Latest:
Dr. Gallego on the Impact of COVID-19 on Cancer Care in SpainJose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.
Latest:
Dr. Vasan on Advancing the Treatment of Small HER2+ Breast CancerNeil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.
Latest:
Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast CancerMichelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Latest:
Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based AnalysesSabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.
Latest:
Dr. Vergote on the Need to Develop Novel Therapies in Endometrial CancerIgnace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.
Latest:
A Dynamic Treatment Landscape Emerges for Early-Stage TNBCStandard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
Latest:
FDA Approvals of Immunotherapy in Gynecology OncologyIn this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.
Latest:
Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ CholangiocarcinomaAlison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
Latest:
Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRCPatrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.
Latest:
Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLCJaneesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.
Latest:
Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung CancerUpal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.
Latest:
Summary of Unmet Needs and Future Directions in MDSExperts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.
Latest:
Optimizing Management of HR+/HER2- BC: Future Directions in CareClosing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Latest:
28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck CancersAlthough the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.
Latest:
Dr Park on the Role of Radiation Therapy in NSCLCHenry S. Park, MD, MPH, discusses the importance of considering radiation therapy in patients with non–small cell lung cancer and how this therapeutic approach can work in concert with targeted therapy and other systemic therapies.
Latest:
The Future of Chronic GvHD TreatmentExpert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.
Latest:
Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCCGeorge Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.
Latest:
Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast CancerAdam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.
Latest:
Sequencing Therapy for MSI-High and MMR-Proficient Endometrial CarcinomasA discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.
Latest:
The Evolving Treatment Landscape in Paroxysmal Nocturnal HemoglobinuriaThe treatment landscape for PNH is rapidly evolving, and clinicians have more effective and convenient treatment options for patients that have helped control the disease and improve survival. T
Latest:
Clinical Trial Diversity Efforts Gain SteamNearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.
Latest:
Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With CancerCaroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.
Latest:
Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple MyelomaDaniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.
Latest:
For Staudt, a Keen Eye Sparks Opportunities to Dig DeeperDriven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.
